Author:
Gane Edward J.,Rouzier Regine,Stedman Catherine,Wiercinska-Drapalo Alicja,Horban Andrzej,Chang Linda,Zhang Ying,Sampeur Pratibha,Nájera Isabel,Smith Patrick,Shulman Nancy S.,Tran Jonathan Q.
Reference21 articles.
1. Diagnosis, management, and treatment of hepatitis C: an update;Ghany;Hepatology,2009
2. Inhibition and binding kinetics of the hepatitis C virus NS3 protease inhibitor ITMN-191 reveals tight binding and slow dissociative behavior;Rajagopalan;Biochemistry,2009
3. Preclinical characteristics of the hepatitis C virus NS3/4A protease inhibitor ITMN-191 (R7227);Seiwert;Antimicrob Agents Chemother,2008
4. Antiviral activity and safety of ITMN-191 in combination with peginterferon alfa-2a and ribavirin in patients with chronic C virus (HCV);Forestier;J Hepatol,2009
5. Terrault N, Cooper C, Balart LA, Larrey D, Box T, Yoshida EM, et al. Phase II randomised, partially-blind, parallel-group study of oral danoprevir (RG7227) with PegIFN α-2a (PEGASYS®) plus ribavirin in treatment-naive genotype 1 patients with CHC: Results of planned Week 12 interim analysis of the ATLAS study. 61st AASLD. 2010.
Cited by
50 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献